MetaVia (MTVA) Accumulated Expenses (2015 - 2026)
MetaVia's (MTVA) quarterly Accumulated Expenses came in at $829000.0 in Q4 2025, up 16.27% YoY from $713000.0 in Q4 2024, and up 26.37% on a QoQ basis from $656000.0 in Q3 2025.
MetaVia (MTVA) Accumulated Expenses (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Accumulated Expenses data on file, last reported at $829000.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 16.27% year-over-year to $829000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $829000.0 (up 16.27% YoY) and the FY2025 annual result came in at $829000.0, up 16.27% from the prior year.
- Accumulated Expenses climbed to $829000.0 in Q4 2025, from $656000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $3.9 million in Q1 2024 to a low of $11000.0 in Q2 2022.
- A 5-year average of $719500.0 and a median of $572000.0 in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 98.64% — and 2023, when it soared 18454.55%.
- Tracing MTVA's Accumulated Expenses over 5 years: stood at $376000.0 in 2021, then sank by 73.4% to $100000.0 in 2022, then surged by 492.0% to $592000.0 in 2023, then grew by 20.44% to $713000.0 in 2024, then increased by 16.27% to $829000.0 in 2025.
- The last three Accumulated Expenses figures came in at $829000.0 (Q4 2025), $656000.0 (Q3 2025), and $552000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 606,000.00 |
| Dec 31, 2025 | 829,000.00 |
| Sep 30, 2025 | 656,000.00 |
| Jun 30, 2025 | 552,000.00 |
| Mar 31, 2025 | 666,000.00 |
| Dec 31, 2024 | 713,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | 592,000.00 |
| Sep 30, 2023 | 13,000.00 |
| Jun 30, 2023 | 2.04 Mn |
| Mar 31, 2023 | 417,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 544,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 174,000.00 |
| Dec 31, 2021 | 376,000.00 |
| Sep 30, 2021 | 922,000.00 |
| Jun 30, 2021 | 811,000.00 |